Ponazuril
| |
Clinical data | |
---|---|
Trade names | Marquis |
AHFS/Drugs.com | FDA Professional Drug Information |
Routes of administration | Oral |
ATCvet code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ECHA InfoCard |
100.157.907 |
Chemical and physical data | |
Formula | C18H14F3N3O6S |
Molar mass | 457.380 g/mol |
3D model (JSmol) | |
| |
| |
|
Ponazuril (INN), sold by Merial, Inc.[1], now part of Boehringer Ingelheim[2], under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona.[3][4] More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.
See also
References
- ↑ "Merial Aquires LEGEND® and MARQUIS® | Boehringer Ingelheim". merial.com. Retrieved 2018-04-30.
- ↑ "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.
- ↑ Marquis FDA Professional Drug Information
- ↑ MacKay, R. J.; Tanhauser, S. T.; Gillis, K. D.; Mayhew, I. G.; Kennedy, T. J. (2008). "Effect of intermittent oral administration of ponazuril on experimentalSarcocystis neuronainfection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.